Head-to-head comparison
CJC-1295/Ipamorelin vs Tesamorelin
Physician-reviewed comparison
CJC-1295/Ipamorelin
Clinical DataLegal to Compound
A combination growth hormone secretagogue pairing a GHRH analog with a ghrelin mimetic.
Tesamorelin
Peer ReviewedFDA Approved
An FDA-approved GHRH analog indicated for HIV-associated lipodystrophy.
Quick Comparison
| Dimension | CJC-1295/Ipamorelin | Tesamorelin |
|---|---|---|
| Category | growth hormone secretagogue | growth hormone secretagogue |
| Classification | GHRH Analog + Growth Hormone Secretagogue | Growth Hormone Releasing Hormone Analog |
| Evidence Rating | Clinical Data | Peer Reviewed |
| Regulatory Status | Legal to Compound | FDA Approved |
| Delivery | Subcutaneous injection | Subcutaneous injection |
| Complexity | 4 / 5 | 4 / 5 |
| Refrigeration | Required | Required |
Dosing Comparison
CJC-1295/Ipamorelin
No dosing data available
Tesamorelin
HIV Lipodystrophy (FDA-Approved)
1.4–2 mg · daily
Body Composition (Off-Label)
1–2 mg · daily
Can You Stack Them?
No known direct interaction between CJC-1295/Ipamorelin and Tesamorelin in our database. However, always consult your provider before combining compounds.
Medical Disclaimer
This comparison is for educational purposes only. Individual responses vary. Consult a qualified healthcare provider before using any compound.